A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays (Q37480106)

20 August 2017

A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays (English)

1 reference

20 August 2017

Elena S Trepakova

1

1 reference

20 August 2017

John Koerner

2

1 reference

20 August 2017

Syril D Pettit

3

1 reference

20 August 2017

Jean-Pierre Valentin

4

1 reference

20 August 2017

HESI Pro-Arrhythmia Committee

5

1 reference

20 August 2017

9 May 2009

1 reference

Journal of Pharmacological and Toxicological Methods

20 August 2017

1 reference

20 August 2017

60

1 reference

20 August 2017

1

1 reference

20 August 2017

45-50

1 reference

QT PRODACT: in vivo QT assay with a conscious monkey for assessment of the potential for drug-induced QT interval prolongation

20 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

Moving towards better predictors of drug-induced torsades de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

The use of electrocardiograms in clinical trials: a public discussion of the proposed ICH E14 regulatory guidance. April 11-12, 2005, Bethesda, MD, USA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

Electrophysiological basis of arrhythmogenicity of QT/T alternans in the long-QT syndrome: tridimensional analysis of the kinetics of cardiac repolarization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

Pentamidine reduces hERG expression to prolong the QT interval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

Q-T and JT dispersion in the elderly with urban hypothermia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

Mechanisms of arsenic-induced prolongation of cardiac repolarization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

Images in cardiovascular medicine. Therapeutic hypothermia-related torsade de pointes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

Pentamidine-induced long QT syndrome and block of hERG trafficking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

Antimony-based antileishmanial compounds prolong the cardiac action potential by an increase in cardiac calcium currents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

Alfuzosin delays cardiac repolarization by a novel mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

Reversal of hypothermia-induced action potential lengthening by the KATP channel agonist bimakalim in isolated guinea pig ventricular muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

In vitro models of proarrhythmia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

A structural basis for drug-induced long QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

QT PRODACT: sensitivity and specificity of the canine telemetry assay for detecting drug-induced QT interval prolongation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

Lack of correlation between exercise and sibenadet-induced changes in heart rate corrected measurement of the QT interval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

Concordance of the toxicity of pharmaceuticals in humans and in animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

QT PRODACT: comparison of non-clinical studies for drug-induced delay in ventricular repolarization and their role in safety evaluation in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

The canine model with chronic, complete atrio-ventricular block

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

Principles of safety pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

Cellular basis of drug-induced torsades de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

Pharmacological modulation of I(Ks): potential for antiarrhythmic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

QT PRODACT: inter-facility variability in electrocardiographic and hemodynamic parameters in conscious dogs and monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

Drug-induced torsade de pointes: from molecular biology to bedside.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

HERG K+ channels: friend and foe.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

Literature-based evaluation of four 'hard endpoint' models for assessing drug-induced torsades de pointes liability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.05.002

10.1016/J.VASCN.2009.05.002

7 January 2021

Identifiers

DOI

1 reference

20 August 2017

1 reference